Head-to-Head Harmonization of Tau Tracers in Alzheimer's Disease

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

620

Participants

Timeline

Start Date

November 23, 2021

Primary Completion Date

May 31, 2027

Study Completion Date

May 31, 2027

Conditions
Alzheimer Disease
Interventions
DRUG

18F-Flortaucipir radiopharmaceutical

Flortaucipir is a PET radiopharmaceutical that binds to tau neurofibrillary tangles. Participants will receive a bolus intravenous injection of approximately 10 millicuries of the radiopharmaceutical.

DRUG

18F-MK-6240 radiopharmaceutical

MK-6240 is a PET radiopharmaceutical that binds to tau neurofibrillary tangles. Participants will receive a bolus intravenous injection of approximately 5 millicuries of the radiopharmaceutical.

DRUG

Amyloid-β radiopharmaceutical (11C-PiB or 18F-Florbetaben or 18F-NAV-4694 or 18F-Florbetapir)

"The clinical sites will use either PiB, Florbetaben, Florbetapir, or NAV-4694 as the amyloid-β PET radiopharmaceutical. The amyloid-β PET radiopharmaceutical binds to amyloid-β plaques.~Participants will receive a bolus intravenous injection of approximately 15 millicuries of the PiB radiopharmaceutical.~Participants will receive a bolus intravenous injection of approximately 8 millicuries of the Florbetaben or NAV-4694 radiopharmaceutical.~Participants will receive a bolus intravenous injection of approximately 10 millicuries of the Florbetapir radiopharmaceutical."

Trial Locations (9)

15260

University of Pittsburgh, Pittsburgh

55905

Mayo Clinic, Rochester

63130

Washington University in St. Louis, St Louis

77030

Houston Methodist Neurological Institute, Houston

94143

University of California San Francisco, San Francisco

94720

Lawrence Berkeley National Laboratory, Berkeley

02912

Brown University, Providence

H3A 0G4

McGill University, Montreal

08025

Sant Pau Biomedical Research Institute, Barcelona

All Listed Sponsors
collaborator

National Institute on Aging (NIA)

NIH

lead

Tharick Pascoal

OTHER